Magic mushroom compound performs as well as escitalopram in depression: NEJM

UK: Researchers in a recent study found no significant difference in antidepressant effects between psilocybin and escitalopram. 

According to the study, published in the New England Journal of Medicine, psychedelic compound psilocybin did not differ significantly from the antidepressant escitalopram in its effects on severe depression symptoms. 

Psychedelic compounds exhibit their action through serotonin receptor (5-HT2A) agonism -- a pathway linked to depression. Psilocybin may have antidepressant properties, but there is a lack of direct comparisons between psilocybin and established treatments for depression. To determine the same, Robin Carhart-Harris, Imperial College London, London, United Kingdom, and colleagues conducted a phase 2, double-blind, randomized, controlled trial involving 59 patients with long-standing, moderate-to-severe major depressive disorder. 

The researchers compared psilocybin with escitalopram, a selective serotonin reuptake inhibitor, over a 6-week period. Patients were assigned in a ratio of 1:1 to receive two separate doses of 25 mg of psilocybin 3 weeks apart plus 6 weeks of daily placebo (psilocybin group; n=30) or two separate doses of 1 mg of psilocybin 3 weeks apart plus 6 weeks of daily oral escitalopram (escitalopram group; n=29); all the patients received psychological support.